Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Katie Ewer et al.|The Lancet|2020Cited by 2.6k
Global distribution and prevalence of hepatitis C virus genotypesJane P. Messina, Eleanor Barnes, Isla Humphreys et al.|Hepatology|2014Cited by 1.6k
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Yanchun Peng, Philip Goulder, Alexander J. Mentzer et al.|Nature Immunology|2020Cited by 1.4k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Gavin Screaton, Wanwisa Dejnirattisai et al.|Cell|2021Cited by 1.2k
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumAekkachai Tuekprakhon, Gavin Screaton, Rungtiwa Nutalai et al.|Cell|2022Cited by 762